Gabriel Morin

Gabriel Morin

Auto-generated profile, based on publicly available information

Gabriel Morin

Université Paris Cité, Paris, France

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
FDFlorence Delestre
Florence Delestre
QVQuitterie Venot
Quitterie Venot
CBCharles Bayard
Charles Bayard
AFAntoine Fraissenon
Antoine Fraissenon
SLSophia Ladraa
Sophia Ladraa
GCGuillaume Canaud
Guillaume Canaud
Alplesib exerts therapeutic effects in a mouse model of lymphatic anomalies and in six patients with lymphatic malformations over 6 months’ treatment.

26 January 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
GMGabriel Morin
Gabriel Morin
CDCaroline Degrugillier-Chopinet
Caroline Degrugillier-Chopinet
MVMarie Vincent
Marie Vincent
AFAntoine Fraissenon
Antoine Fraissenon
HAHélène Aubert
Hélène Aubert
GCGuillaume Canaud
Guillaume Canaud
PIK3CA-related overgrowth spectrum (PROS) includes rare genetic conditions due to gain-of-function mutations in the PIK3CA gene. There is no approved medical therapy for patients with PROS, and alpelisib, an approved PIK3CA inhibitor in oncology, showed promising results in preclinical models and in patients. Here, we report for the first time the outcome of two infants with PROS having life-threatening conditions treated with alpelisib (25 mg) and monitored with pharmacokinetics. Patient 1 was an 8-mo-old girl with voluminous vascular malformation. Patient 2 was a 9-mo-old boy presenting with asymmetrical body overgrowth and right hemimegalencephaly with West syndrome. After 12 mo of follow-up, alpelisib treatment was associated with improvement in signs and symptoms, morphological lesions and vascular anomalies in the two patients. No adverse events were reported during the study. In this case series, pharmacological inhibition of PIK3CA with low-dose alpelisib was feasible and associated with clinical improvements, including a smaller size of associated complex tissue malformations and good tolerability.

25 July 2024 in New England Journal of Medicine
Verified
Journal Article
Closed access
AFAntoine Fraissenon
Antoine Fraissenon
CBCharles Bayard
Charles Bayard
GMGabriel Morin
Gabriel Morin
SBSandro Benichi
Sandro Benichi
CHClément Hoguin
Clément Hoguin
GCGuillaume Canaud
Guillaume Canaud
KRAS gain-of-function mutations are frequently observed in sporadic arteriovenous malformations. The mechanisms underlying the progression of such KRAS-driven malformations are still incompletely understood, and no treatments for the condition are approved. Here, we show the effectiveness of sotorasib, a specific KRAS G12C inhibitor, in reducing the volume of vascular malformations and improving survival in two mouse models carrying a mosaic Kras G12C mutation. We then administered sotorasib to two adult patients with severe KRAS G12C-related arteriovenous malformations. Both patients had rapid reductions in symptoms and arteriovenous malformation size. Targeting KRAS G12C appears to be a promising therapeutic approach for patients with KRAS G12C-related vascular malformations. (Funded by the European Research Council and others.).

9 December 2022 in Science Advances
Verified
Journal Article
Open access
SLSophia Ladraa
Sophia Ladraa
LZLola Zerbib
Lola Zerbib
CBCharles Bayard
Charles Bayard
AFAntoine Fraissenon
Antoine Fraissenon
QVQuitterie Venot
Quitterie Venot
GCGuillaume Canaud
Guillaume Canaud
PIK3CA -related overgrowth syndrome (PROS) is a genetic disorder caused by somatic mosaic gain-of-function mutations of PIK3CA . Clinical presentation of patients is diverse and associated with endocrine disruption. Adipose tissue is frequently involved, but its role in disease development and progression has not been elucidated. Here, we created a mouse model of PIK3CA -related adipose tissue overgrowth that recapitulates patient phenotype. We demonstrate that PIK3CA mutation leads to GLUT4 membrane accumulation with a negative feedback loop on insulin secretion, a burst of liver IGFBP1 synthesis with IGF-1 sequestration, and low circulating levels. Mouse phenotype was mainly driven through AKT2. We also observed that PIK3CA mutation induces metabolic reprogramming with Warburg-like effect and protein and lipid synthesis, hallmarks of cancer cells, in vitro, in vivo, and in patients. We lastly show that alpelisib is efficient at preventing and improving PIK3CA -adipose tissue overgrowth and reversing metabolomic anomalies in both animal models and patients.

1 April 2019 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
GMGabriel Morin
Gabriel Morin
AMArthur Mageau
Arthur Mageau
KBKhadija Benali
Khadija Benali
RBRemi Bertinchamp
Remi Bertinchamp
EPEve Piekarski
Eve Piekarski
KSKarim Sacre
Karim Sacre

21 November 2025 in EMBO Molecular Medicine
Verified
Journal Article
Open access
GMGabriel Morin
Gabriel Morin
IGIlaria Galasso
Ilaria Galasso
GCGuillaume Canaud
Guillaume Canaud
Vascular malformations (VMs) are congenital disorders characterized by structurally abnormal blood and lymphatic vessels. Advances in genetics have revealed that most sporadic VMs result from post-zygotic variants in genes involved in key endothelial signaling pathways, including the phosphoinositide-3-kinase (PI3K) and the mitogen-associated proliferation kinase (MAPK) pathways. As these variants are shared with cancer, genetics now have theragnostic impact by helping predict relevant targeted therapies. mTOR and PI3Kα inhibitors such as sirolimus and alpelisib have shown promising efficacy in slow-flow VMs, while reports have suggested that MAPK inhibitors such as trametinib may improve arteriovenous malformations. Despite these advances, several challenges remain, including obtaining accurate genetic diagnosis, enhancing treatment efficacy while mitigating drug-related toxicities, and personalizing multimodal treatment strategies. Emerging approaches such as mutant-selective inhibitors, proteolysis-targeting chimeras, and gene therapy hold promises for improving treatment specificity and minimizing adverse effects. This review provides an overview of the genetic bases of VMs, recent advances in targeted therapies, and future directions in the field, highlighting the ongoing evolution of precision medicine for VMs.